Search

Your search keyword '"Bombardieri, G."' showing total 149 results
Start Over Author "Bombardieri, G."
149 results on '"Bombardieri, G."'

1. A territory-wide opportunistic, hospital-based HCV screening in the general population from northern Italy: The 1969–1989 birth-cohort

Author

D'Ambrosio, R, Piccinelli, S, Beccalli, B, Spinetti, A, Puoti, M, Fagiuoli, S, Magni, C, Vavassori, A, Sacchi, P, Castaldi, S, Bombardieri, G, Farina, C, Buoro, S, Amorosi, A, Corradin, M, Cereda, D, Lampertico, P, D'Ambrosio R., Piccinelli S., Beccalli B., Spinetti A., Puoti M., Fagiuoli S., Magni C. F., Vavassori A., Sacchi P., Castaldi S., Bombardieri G., Farina C., Buoro S., Amorosi A., Corradin M., Cereda D., Lampertico P., D'Ambrosio, R, Piccinelli, S, Beccalli, B, Spinetti, A, Puoti, M, Fagiuoli, S, Magni, C, Vavassori, A, Sacchi, P, Castaldi, S, Bombardieri, G, Farina, C, Buoro, S, Amorosi, A, Corradin, M, Cereda, D, Lampertico, P, D'Ambrosio R., Piccinelli S., Beccalli B., Spinetti A., Puoti M., Fagiuoli S., Magni C. F., Vavassori A., Sacchi P., Castaldi S., Bombardieri G., Farina C., Buoro S., Amorosi A., Corradin M., Cereda D., and Lampertico P.

Abstract

Background and Aim: The World Health Organization (WHO) goal of Hepatitis C Virus (HCV) elimination by 2030 rose awareness about the need of screening plans, worldwide. In Italy, graduated screening starting from people born in 1969–1989 might be the most-effective strategy. We performed an opportunistic HCV screening study in the general population attending health facilities in Lombardy region, Northern Italy. Methods: This is a prospective, multicenter, territory-wide, opportunistic study supported by the Regional Government of Lombardy, Italy. Between June 2022 and December 2022, all subjects born in 1969–1989, hospitalized or accessing blood collection centres were offered anti-HCV and HCV–RNA tests. Patients with known anti-HCV positivity and/or previous anti-HCV treatment were excluded. Demographic features were uploaded into a regional web-based platform. Results: In total, 120 193 individuals were screened in 75 centres. Mean age was 44 (±6) years, 65.2% were females, 83.7% were tested at blood collection centres. Anti-HCV tested positive in 604 (0.50%) subjects: mean age 47 (±5), 51.1% females. HCV seroprevalence was higher in males (p < 0.00001), elderly (p < 0.00001) and in- vs. outpatients (p = 0.0009). HCV–RNA was detectable in 125 out of 441 (28.3%) anti-HCV positive subjects. Actively infected patients were 46 (±6) years old, mainly males (56.8%). The overall prevalence of active HCV infection was 0.10%, higher in elderly (p = 0.0003) and in in-patients (p = 0.0007). Among 93 HCV–RNA positive patients, the median age was 48 years, 58% males, 62% Italian born, median HCV–RNA levels were 6,1 log IU/mL, liver stiffness measurement (LSM) values 5.5 (3.1–29.9) kPa and ALT levels 48 U/L. Conclusions: The prevalence of active HCV infection in the 1969–1989 population attending health facilities in Lombardy was low. Most viremic patients were Italian-born, with mild liver disease but high-HCV–RNA levels. Due to the higher prevalence in the elderly, the

Published
2023

9. Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study

Author

Morisco, F, Stroffolini, T, Medda, E, Amoruso, Dc, Almasio, Pl, Villa, E, Zuin, M, Paris, B, Stanzione, M, Caporaso, N, NADIR Study Group, Aceti, A, Amaddeo, G, Ancarani, F, Arcuri, P, Attili, A, Bandiera, F, Bellati, G, Benigno, R, Benini, F, Bombardieri, G, Bruno, S, Capretti, A, Carrara, M, Cottone, C, Cozzolongo, R, Demelia, L, Di Gaetano, G, Esposito, P, Fanelli, G, Gaeta, Gb, Giannini, Eg, Giorgini, A, Grieco, A, Guadagnino, V, Lanzini, A, Lo Bello, S, Lupo, S, Maracci, M, Marchi, S, Martines, D, Mazzella, G, Miele, L, Milan, M, Milani, S, Minoli, G, Montalto, G, Morrone, A, Nosotti, L, Paroli, M, Pastore, G, Persico, Marcello, Piccinino, F, Pinzello, Gb, Pozzi, M, Roffi, L, Russello, M, Russo, M, Sagnelli, E, Savarino, V, Soccorsi, F, Squadrito, G, Tabone, M, Tarsetti, F, Tesini, Em, Testa, R, Tripi, S, Gianfranca, S, Vandelli, C, Zignego, A. L., Morisco, F., Stroffolini, T., Medda, E., Amoruso, D. C., Almasio, P. L., Villa, E., Zuin, M., Paris, B., Stanzione, M., Caporaso, N., Nadir Study Group, Mazzella, Giuseppe, Morisco, F, Stroffolini, T, Medda, E, Amoruso, DC, Almasio, PL, Villa, E, Zuin, M, Paris, B, Stanzione, M, Caporaso, N, Montalto, G, Morisco, Filomena, T., Stroffolini, E., Medda, D. C., Amoruso, P. L., Almasio, E., Villa, M., Zuin, B., Pari, M., Stanzione, and Caporaso, Nicola

Subjects
Adult, Male, non-responders, relapser, Genotype, body mass index, cirrhosis, hepatitis c virus, nonresponder, pegylated-interferon, Infectious Disease, Hepacivirus, virus, Interferon alpha-2, Antiviral Agents, Polyethylene Glycol, Polyethylene Glycols, Medication Adherence, hepatitis C, Risk Factors, Retrospective Studie, Virology, Ribavirin, Humans, Age Factor, Treatment Failure, Retrospective Studies, Aged, Antiviral Agent, Settore MED/12 - Gastroenterologia, HCV, Antiviral therapy, Body mass index, Cirrhosis, Hepatitis C virus, Nonresponder, Pegylated-interferon, Relapser, Cirrhosi, Hepaciviru, Hepatology, Risk Factor, Age Factors, Interferon-alpha, Hepatitis C, Chronic, Middle Aged, Recombinant Protein, Recombinant Proteins, Italy, RNA, Viral, Female, Hepatitis C viru, Human
Abstract

There is a lack of information on the characteristics of patients with chronic hepatitis C virus infection (HCV) who fail to respond to antiviral treatment. We studied HCV-positive subjects with chronic liver diseases treated with pegylated-interferon (PEG-IFN) and ribavirin (RBV) who failed to clear HCV in routine clinical practice. A total of 2150 consecutive adult patients treated with PEG-IFN plus RBV therapy in 46 Italian centres between 1 July 2004, and 30 June 2005, were studied. Of the 2150 patients, 923 (42.9%) (M/F 585/335, mean age 54.8 years) failed to achieve a serum HCV-RNA clearance. Of these 923 patients, 429 (46.5%) were nonresponders, 298 (32.3%) relapsers, 168 (18.2%) drop-outs for noncompliance or adverse events and 28 (3.0%) were lost during follow-up. Overall, 642 (70.6%) patients received adequate therapy (defined as more than 80% of the drug doses for >80% of the time). Genotypes 1-4 were observed in 76.9% of cases; genotypes 2-3 in 21.2% and mixed in 1.9%, respectively. Multiple logistic regression analysis identified genotypes 1 and 4 as the sole independent predictors of the likelihood of nonresponse to therapy compared with relapse (OR: 4.38; 95% CI = 2.28-8.4). Age older than 65 years was the sole independent factor associated with no adherence to therapy (OR: 2.22; 95% CI = 1.36-3.62). Patients who fail to respond to treatment are a nonhomogeneous population with different features, and the sole factor that discriminates nonresponse from relapse is the distribution of genotypes 1-4. Co-morbidities are unable to determine the type of treatment failure and inadequate adherence to therapy mostly affects patients older than 65 years of age. © 2009 Blackwell Publishing Ltd.

Published
2010

10. HCC PERSONALIZED TREATMENT IN THE MULTIMODAL MANAGEMENT ERA: THE HEPATOCAT GROUP EXPERIENCE

Author

Ponziani, Francesca Romana, Zocco, Maria Assunta, De Gaetano, Anna Maria, Novi, M, Siciliano, M, Milani, Alessandro, Annicchiarico, Eb, Miele, Luca, Rinninella, Emanuele, Tortora, Annalisa, Ainora, Maria Elena, Gasbarrini, Giovanni Battista, Agnes, Salvatore, Bombardieri, G, Giuliante, Felice, Grieco, A, Nuzzo, Gennaro, Pompili, Maurizio, Rapaccini, Gian Ludovico, Di Stasio, Enrico, and Gasbarrini, Antonio

Subjects
N/A, Settore MED/12 - GASTROENTEROLOGIA
Published
2010

14. A 5-year prospective study of the late resolution of chronic hepatitis C after antiviral therapy

Author

Annicchiarico, Brigida Eleonora, Siciliano, Massimo, Avolio, Alfonso Wolfango, Grillo, Rita Luciana, Bombardieri, G., Avolio, Alfonso Wolfango (ORCID:0000-0003-2491-7625), Annicchiarico, Brigida Eleonora, Siciliano, Massimo, Avolio, Alfonso Wolfango, Grillo, Rita Luciana, Bombardieri, G., and Avolio, Alfonso Wolfango (ORCID:0000-0003-2491-7625)

Abstract

Persistence of hepatitis C virus (HCV) in serum is assured after any course of antiviral therapy that failed to obtain a sustained virological response.

Published
2007

15. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon

Author

Fattovich, G., Giustina, G., Favarato, S., Ruol, A., Macarri, G., Orlandi, E., Iaquinto, G., Ambrosone, L., Francavilla, A., Pastore, G., Santantonio, M. T., Romagno, D., Bolondi, L., Sofia, S., Marchesini, A., Pisi, E., Mazzella, G., Roda, E., Attaro, L., Chiodo, E., Mori, E., Verucchi, G., Lanzini, A., Salmi, A., Calvi, B., Bozzetti, E., Radaeli, E., Bernasconi, M., Pilleri, G., Bacca, D., Romano, G., Mastrapasqua, G., Cozzolongo, R., Cacopardo, B., Nunnari, A., Blasi, A., Sala, L. O., Minoli, G., Sangiovanni, A., Spinzi, G. C., Colombo, A., Camassa, M., Riva, D., Maggi, G., Boccia, S., Gualandi, G., Nucci, A., Pacini, F., Marino, N., Mazzotta, E., La Mura, A., Pompei, A. G., Casinelli, K., Petrosillo, N., Giacchino, R., Timitilli, A., Spiga, E., Corsetti, M., Menicagli, V., Tucci, A., Bissoli, E., Raimondo, G., Rodino, G., Bellobuono, A., Ideo, G., Colombo, M., Pacchetti, S., Rumi, M. R., Battezzati, P. M., Bruno, S., Podda, M., Zuin, M., Fargion, S., Fiorelli, G., Gellmann, E., Vandelli, C., Ventura, E., Manenti, F., Villa, E., Caporaso, N., Coltorti, M., Morisco, E., Del Vecchio-Blanco, C., di Santolo, S. S., Di Nunzio, S., Ruggiero, G., Zampino, R., Ascione, A., De Luca, M., Galeota-Lanza, A., Aprea, L., Sagnelli, E., Felaco, E. M., Piccinino, E., Ballare, M., Monteverde, A., Tappero, G., Sanna, G., Alberti, A., Bonetti, P., Casarin, C., Diodati, G., Tremolada, E., Naccarato, R., Chiaramonte, M., Floreani, M. R., Almasio, P., Craxi, A., Loiacono, O., Pagliaro, L., Fiaccadori, E., Giuberti, T., Belloni, G., Bernardini, E., Buscarini, L., Sbolli, G., Giudici-Cipriani, A., Marenco, G., Mazzaro, C., Massari, M., Fornaciari, G., Plancher, A., Gasbarrini, G., Grieco, A., Luchetti, R., Rapaccini, G. L., Bombardieri, G., Di Virgilio, D., Bruno, G., Ricci, G. L., Hassan, G., Mari, T., Scalisi, I., Colloredo, G., Frunzio, A., Tabone, M., Costa, C., Rosina, E., Saracco, G., Verme, G., Frezza, M., Urban, E., Capra, E., Casaril, M., Corrocher, R., and Benetti, G. P.

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Hepatitis, Viral, Human, Alpha interferon, Poison control, Chronic viral hepatitis, Interferon alfa, Side effects, Gastroenterology, Autoimmune Diseases, Internal medicine, Medicine, Humans, Adverse effect, Child, Aged, Retrospective Studies, Hepatitis, Hepatology, business.industry, Thyroid disease, Mental Disorders, Infant, Newborn, Infant, Middle Aged, medicine.disease, Recombinant Proteins, Surgery, Bone marrow suppression, Child, Preschool, Chronic Disease, Interferon Type I, Female, business, Viral hepatitis, medicine.drug
Abstract

Aims: The aim of this study was to assess the incidence of fatal, life-threatening side effects and the de novo appearance of non-hepatic morbidity during interferon alfa therapy for chronic viral hepatitis. The relationship of these adverse events to actual total dose and duration of interferon was also evaluated. Methods: We conducted a retrospective study at 73 Italian centers of 11 241 consecutive patients with chronic vital hepatitis who underwent interferon alfa treatment. Results: Five patients died during interferon therapy due to liver failure ( n =4) or complications arising from sepsis. Life-threatening side effects were observed in eight patients: two cases where depression developed and led to a suicide attempt and six patients with bone marrow suppression (granulocytes 3 or platelets 3 ). These symptoms and signs completely disappeared after interferon withdrawal. During interferon treatment, 131 patients developed the following de novo non-hepatic disorders: symptomatic thyroid disease ( n =71), impotence ( n =5), systemic autoimmune disease ( n =5), immune-mediated dermatologic disease ( n =14), diabetes mellitus ( n =10), cardiovascular disease ( n =7), psychosis n =10), seizures ( n =4), peripheral neuropathy ( n =3) and hemolytic anemia ( n =2). Most of these complications are reversible or can be ameliorated. Fatal or life-threatening side effects were not related to actual total dose or duration of interferon alfa, while the majority of patients with de novo non-hepatic morbidity received medium/high doses ( > 200 million units) of interferon alfa or were treated for periods longer than 16 weeks (68% and 80%, respectively). Conclusions: Treatment with interferon alfa may have fatal or life-threatening side effects, their incidence in this study being low (0.04% and 0.07%, respectively) and perhaps no different than in untreated patients with chronic viral hepatitis. Moreover de novo non-hepatic morbidity occurred in 1.2% of patients, and the dose and duration of interferon therapy seem important in determining the frequency of this complication. The development of clinically-overt thyroid disease was most common.

Published
1996

17. P.1.303: HIGH DOSE AMOXICILLIN-BASED FIRST LINE REGIMEN IS EQUIVALENT TO SEQUENTIAL THERAPY IN THE ERADICATION OF H. PYLORI INFECTION

Author

Franceschi, F., primary, Campanale, M., additional, Finizio, R., additional, Barbaro, F., additional, Tortora, A., additional, Gigante, G., additional, Cesario, V., additional, Calcinaro, S., additional, Marsiliani, D., additional, Carroccia, A., additional, Silveri, N. Gentiloni, additional, Currò, D., additional, Cammarota, G., additional, Gasbarrini, G., additional, Bombardieri, G., additional, and Gasbarrini, A., additional

Published
2011
Full Text
View/download PDF

18. P.1.175: NEW PERSPECTIVES IN TREATMENT OF MULTINODULAR UNRESECTABLE HEPATOCELLULAR CARCINOMA: BALLOON-OCCLUDED PERCUTANEOUS RADIO-FREQUENCY THERMOABLATION (RFA) FOLLOWED BY TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE)

Author

Iezzi, R., primary, Cesario, V., additional, Ponziani, F.R., additional, Gigante, G., additional, Rinninella, E., additional, Campanale, C., additional, Di Rienzo, T.A., additional, Caracciolo, G., additional, Zocco, M.A., additional, De Gaetano, A.M., additional, Siciliano, M., additional, Milani, A., additional, Miele, L., additional, Grieco, A., additional, Agnes, S., additional, Bombardieri, G., additional, Nuzzo, G., additional, Giuliante, F., additional, Pompili, M., additional, Rapaccini, G.L., additional, Basso, M., additional, Gasbarrini, G., additional, Bonomo, L., additional, and Gasbarrini, A., additional

Published
2011
Full Text
View/download PDF

19. P.1.161: HCC PERSONALIZED TREATMENT IN THE MULTIMODAL MANAGEMENT ERA: HEPATOCAT GROUP EXPERIENCE

Author

Ponziani, F.R., primary, Zocco, M.A., additional, De Gaetano, A.M., additional, Novi, M.L., additional, Siciliano, M., additional, Milani, A., additional, Annicchiarico, B.E., additional, Rinninella, E., additional, Gigante, G., additional, Cesario, V., additional, Caracciolo, G., additional, Tortora, A., additional, Garcovich, M., additional, Gasbarrini, G., additional, Agnes, S., additional, Bombardieri, G., additional, Grieco, A., additional, Nuzzo, G., additional, Pompili, M., additional, Rapaccini, G.L., additional, Giuliante, F., additional, Di Stasio, E., additional, and Gasbarrini, A., additional

Published
2011
Full Text
View/download PDF

20. 634 BALLOON-OCCLUDED PERCUTANEOUS RADIO-FREQUENCY THERMAL ABLATION (RFA) PLUS TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE): A NEW COMBINED SINGLE-STEP THERAPY FOR TREATMENT OF MULTINODULAR UNRESECTABLE HEPATOCELLULAR CARCINOMA

Author

Iezzi, R., primary, Cesario, V., additional, Ponziani, F.R., additional, Gigante, G., additional, Caracciolo, G., additional, Rinninella, E., additional, Zocco, M.A., additional, de Gaetano, A.M., additional, Siciliano, M., additional, Milani, A., additional, Miele, L., additional, Gasbarrini, G., additional, Agnes, S., additional, Bombardieri, G., additional, Giuliante, F., additional, Grieco, A., additional, Nuzzo, G., additional, Pompili, M., additional, Basso, M., additional, Rapaccini, G.L., additional, di Stasio, E., additional, Bonomo, L., additional, and Gasbarrini, A., additional

Published
2011
Full Text
View/download PDF

21. P.1.181: ACCURACY OF CO2 CORRECTED H2 AND CH4 VALUES IN BREATH TESTS

Author

Campanale, M., primary, Scarpellini, E., additional, Tortora, A., additional, Bertucci, F., additional, Purchiaroni, F., additional, Maurizio, G., additional, Lauritano, C.E., additional, Di Maurizio, L., additional, Ojetti, V., additional, Gasbarrini, G., additional, Bombardieri, G., additional, and Gasbarrini, A., additional

Published
2011
Full Text
View/download PDF

22. P.1.38: SEQUENTIAL AND STANDARD LEVOFLOXACIN-BASED H. PYLORI ERADICATING REGIMENS COMPARED TO QUADRUPLE THERAPY: EFFECT OF LEVOFLOXACIN DOSAGE AND WAY OF ADMINISTRATION

Author

Franceschi, F., primary, Finizio, R., additional, Campanale, M., additional, Barbaro, F., additional, Gigante, G., additional, Tortora, A., additional, Santarelli, L., additional, Cesario, V., additional, Calcinaro, S., additional, Marsiliani, D., additional, Carroccia, A., additional, Silveri, N. Gentiloni, additional, Currò, D., additional, Cammarota, G., additional, Gasbarrini, G., additional, Bombardieri, G., additional, and Gasbarrini, A., additional

Published
2011
Full Text
View/download PDF

38. Patent side branches do not affect coronary blood flow in internal thoracic artery-left anterior descending anastomosis: An experimental study

Author

Pragliola, C., Gaudino, M., Bombardieri, G., Barilaro, C., Bruno, P., Varano, C., Santoro, T., and Possati, G.

Abstract

Background: It has been reported that large side branches of internal thoracic artery grafts may steal flow from the coronary circulation. Material an. Methods: To assess the importance of the side branches, we measured the proximal and distal flow and pressures (mean subclavian artery pressure and mean arterial anastomotic pressure) at baseline and during infusion of adenosine (0.5 mg/kg/min) in 10 Landrace pigs in which an internal thoracic artery-left anterior descending anastomosis was constructed without interruption of the side branches. The difference between proximal and distal flow was considered to represent the blood flow of the internal thoracic artery side branches. Measurements were then repeated after surgical occlusion of all the side branches. Results: At baseline, blood flow of the side branches represented 18% of the total flow in the proximal internal thoracic artery, and this percentage remained constant under the infusion of adenosine, which caused a 220% increase of the cardiac index and a 368% increase of the proximal flow. The infusion reduced the gradient along the left internal thoracic artery (mean subclavian artery pressure-mean arterial anastomotic pressure) from 15 to 10 mm Hg (P = .02) as the result of a lower mean subclavian artery pressure, although the mean arterial anastomotic pressure remained constant. Interruption of all the side branches resulted in a small and not significant increase in distal flow even after adenosine infusion. Conclusion: These observations suggest that blood flow in the side branches is minimal either at baseline and under combined systemic and coronary vasodilation. Clinically significant flow steal from the coronary circulation to the internal thoracic artery side branches seems then unlikely. (J Thorac Cardiovasc Surg 1999;118:66-70)

Published
1999
Full Text
View/download PDF

40. Degradation of cystaldimine, the product of oxidative deamination of cystamine

Author

de Marco, C., Bombardieri, G., Riva, F., Dupré, S., and Cavallini, D.

Abstract

1.(1) Cystamine is oxidatively deaminated to the corresponding cyclized aminoaldehyde, cystaldimine, by diamineoxidase (diamine: O2oxidoreductase (deaminating), EC 1.4.3.6).Cystaldimine undergoes further degradation giving rise to thiocysteamine and a C2fragment.2.(2) Thiocysteamine may be trapped by monoiodoacetic acid and the resulting mixed disulphide 1-amino-3,4-dithiapentane-5-carboxylic acid (carboxymethylthiocysteamine) has been detected by paper, and column, chromatography.3.(3) Thiocysteamine, being a very unstable compound, spontaneously produces cysteamine, which also has been trapped by monoiodoacetic acid as carboxymethyl cysteamine, and detected by column chromatography.4.(4) On the basis of the present and previous results, a cycle of reactions is suggested, leading to extensive degradation of cystamine to ammonia, sulphur and a C2compound.

Published
1965
Full Text
View/download PDF

42. Visual evoked potential recordings in hepatic encephalopathy and their variations during branched chain amino-acid treatment

Author

Bombardieri G, Gl, Gigli, Bernardi L, Raffaele Ferri, Grassi C, and Milani A

Subjects
Adult, Male, Ammonia, Ethanolamines, Hepatic Encephalopathy, Evoked Potentials, Visual, Humans, Female, Middle Aged, Octopamine, Amino Acids, Branched-Chain, Aged
Abstract

In fourteen subjects with various stages of hepatic encephalopathy (HE), Visual Evoked Potential (VEP) recording and blood ammonia (NH3), octopamine (OCT) and phenylethanolamine (PEA) determinations were performed before and during a four-day treatment with branched chain amino acid (BCAA) i.v. infusion. All the subjects with HE showed significant basal VEP alterations, namely an increased latency and a lowered amplitude of the P100 wave, in comparison with a control group of 26 normal subjects. A significant improvement in P100 wave amplitude occurred just about 60' after the beginning of BCAA infusion, while P100 latency was still unaffected, as were OCT, PEA and NH3 levels. After the fourth day of BCAA treatment, both P100 wave amplitudes and latencies were strongly improved, together with OCT, PEA and NH3 levels. VEP improvements seemed to be well correlated with HE clinical evolution, and were able to detect modifications of central nervous system reactivity earlier than serum parameters.

Published
1985

Catalog

Books, media, physical & digital resources
See catalog results